Investment highlights
Investment highlights
-
Focus on developing a novel treatment for inflammatory and autoimmune diseases targeting the melanocortin system
-
Several near-term value inflection points from Phase II development and other corporate activities
-
First-in-class compound with unique biology and once-daily dosing designed to have versatility across several indications
-
Fortified IP portfolio providing protection until 2042
-
Experienced management team and BoD with strong track record in drug development and deal making
-
Continually evaluating compelling business development opportunities
Upcoming news flow

- Initiate Phase IIb programme

- Initiate confirmatory virus-induced respiratory insufficiency trial, paving the way for Emergency Use Approval in select countries

- Complete Phase IIa in re-designed study

- Uplist to Nasdaq Stockholm Main Market (1H22)
- Additional IP
- Discovery of new assets
- Potential business development